Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Dynavax Technologies (NQ: DVAX )

13.79 +0.09 (+0.66%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 1, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,829,006
Open 13.65
Bid (Size) 13.20 (30)
Ask (Size) 13.99 (3)
Prev. Close 13.70
Today's Range 13.48 - 13.89
52wk Range 9.420 - 15.15
Shares Outstanding 128,489,060
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Dynavax Technologies (DVAX) Q3 2023 Earnings Call Transcript
DVAX earnings call for the period ending September 30, 2023. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Earnings Preview For Dynavax Technologies
Via Benzinga

Performance

YTD
+30.09%
+30.09%
1 Month
-1.99%
-1.99%
3 Month
-3.09%
-3.09%
6 Month
+19.39%
+19.39%
1 Year
+8.41%
+8.41%

More News

Read More
Cramer Suggests Buying Fast Food Chain Owner Of Popeye's, Burger King: Here's Why
Via Benzinga
Dynavax Technologies Stock Sees Renewed Technical Strength
Via Investor's Business Daily
Atlassian, Universal Display, Booking, Dropbox And Other Big Stocks Moving Higher On Friday
Via Benzinga
Preview: Dynavax Technologies's Earnings
Via Benzinga
5 Value Stocks In The Healthcare Sector
Via Benzinga
Dynavax Technologies (DVAX) Q2 2023 Earnings Call Transcript
Via The Motley Fool
Overview Of Value Stocks In The Healthcare Sector
Via Benzinga
5 Value Stocks In The Healthcare Sector
Via Benzinga
A Look Into Healthcare Sector Value Stocks
Via Benzinga
The 7 Best Stocks Under $15 to Buy in June 2023
Via InvestorPlace
The Latest Analyst Ratings for Dynavax Technologies
Via Benzinga
Dynavax Technologies's Return On Capital Employed Insights
Via Benzinga
JMP Securities Maintains Market Outperform Rating for Dynavax Technologies: Here's What You Need To Know
Via Benzinga
Dynavax Technologies (DVAX) Q1 2023 Earnings Call Transcript
Via The Motley Fool
7 Biotech Stocks Sitting in the Sweet Spot
Via InvestorPlace
The Top 7 Growth Stocks in Biotech
Via InvestorPlace
Dynavax Technologies (DVAX) Q4 2022 Earnings Call Transcript
Via The Motley Fool
Jim Cramer On This Stock Up 2% Over 6 Months: 'You've Got A Real Winner There'
Via Benzinga
Clover Provides Updates on COVID-19 Vaccine Commercial Launch and Strategic Priorities in 2023
From Clover Biopharmaceuticals
Via GlobeNewswire
The 7 Most Undervalued Long-Term Stocks to Buy in January
Via InvestorPlace
Our 7 Top Small-Cap Stock Picks for 2023
Via InvestorPlace
Dynavax Adjuvant Based COVID-19 Vaccine Lowers The Risk Of Transmission
Via Benzinga
Clover’s Vaccine Candidate Reduced Household Transmission of SARS-CoV-2 in Study Published in Clinical Infectious Diseases
From Clover Biopharmaceuticals
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.